Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Inventory Average (2019 - 2025)

Coherus Oncology (CHRS) has disclosed Inventory Average for 7 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Inventory Average fell 89.93% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, down 89.93% year-over-year, with the annual reading at $3.7 million for FY2025, 88.96% down from the prior year.
  • Inventory Average hit $2.6 million in Q4 2025 for Coherus Oncology, down from $3.3 million in the prior quarter.
  • In the past five years, Inventory Average ranged from a high of $65.4 million in Q3 2023 to a low of $2.6 million in Q4 2025.
  • Historically, Inventory Average has averaged $37.7 million across 5 years, with a median of $38.1 million in 2021.
  • Biggest five-year swings in Inventory Average: skyrocketed 265.23% in 2021 and later tumbled 94.02% in 2025.
  • Year by year, Inventory Average stood at $37.6 million in 2021, then decreased by 11.59% to $33.3 million in 2022, then surged by 94.54% to $64.7 million in 2023, then plummeted by 59.93% to $25.9 million in 2024, then tumbled by 89.93% to $2.6 million in 2025.
  • Business Quant data shows Inventory Average for CHRS at $2.6 million in Q4 2025, $3.3 million in Q3 2025, and $4.0 million in Q2 2025.